MedTrace Logo

Association of Plasma Metabolomic Biomarkers with Chronic Ischemic White Matter Injury

NCT06608251 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-09-23

No results posted yet for this study

Summary

The cases were screened according to the inclusion criteria, and after the patients signed the informed consent, the clinical data were collected, the imaging data were evaluated, and blood samples were taken for follow-up measurements. In the early morning of the second day after the patient was enrolled, 5mL of peripheral venous blood was drawn and sent to the neurology laboratory of our hospital for separation, and the detection of plasma metabolomics markers was performed.

Conditions

  • Myelinopathy

Interventions

DIAGNOSTIC_TEST

white matter lesion

According to the results of magnetic resonance, they were divided into white matter degeneration group and non-white matter degeneration group

Sponsors & Collaborators

  • Nanjing First Hospital, Nanjing Medical University

    lead OTHER

Principal Investigators

  • Ying Zhang, Doctor · Nanjing First Hospital, Nanjing Medical University

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2025-05-31
Completion
2025-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06608251 on ClinicalTrials.gov